Tag: Bristol-Myers

Bristol Myers Boosts Cancer Drug Portfolio With $4.1 Billion Turning Point Deal

June 4, 2022
Bristol-MyersBusiness & Economycancer drugCompanies
0 Comment

Bristol Myers Squibb Co. said on Friday it will acquire drug developer Turning Point Therapeutics Inc. for $4.1 billion in cash to help bolster its arsenal of cancer drugs. Turning Point’s lead drug, repotrectinib, targets mutations in certain proteins in the body that lead to unchecked cell growth. Bristol Myers will pay $76 per Turning…

Read More

Bristol Myers Drug Wins First US Approval for Graft Versus Host Disease Prevention

December 15, 2021
approvalBristol-MyersHealth & SafetyHealth NewsHot DiseaseLifestyleMind & Bodyprevention
0 Comment

Bristol Myers Squibb Co.’s Orencia on Wednesday became the first drug to win U.S. approval for the prevention of acute Graft versus Host Disease (aGvHD), a potentially fatal complication that could occur after a stem cell transplant. The Food and Drug Administration (FDA) has cleared the drug in combination with certain immunosuppressants for use in…

Read More